ImmunoGen Message Board - Msg: 30630180

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: more100 who wrote (5569)	6/21/2016 6:49:06 PM
From: Gary Mohilner	Read Replies (1) of 5665

I bought substantially more at $3.50, but with it setting new lows daily it's approaching its book value after the $100 million they'll receive is factored in. In my mind this is crazy given the pipeline, regardless of how poorly what happened with IMGN853 was handled. I'm frankly uncertain if they'd abandoned the drug if it wouldn't be priced higher than it is today. It's sad, but right no nothing counts but IMGN853. Had they never said they'd anticipated registrational Phase II's, the stock might be $15 on news that on the strength of Phase I/II Trials they were moving directly into Phase III. In almost all cases, Phase I/II's lead to larger Phase II's before Phase III's are considered. Like most things, I believe this too will pass as more becomes known on other drugs, increasing Kadcyla sales, etc. On the actual initiation of Phase III I'd be surprised if we weren't back in double digits. I would think we're awfully close to the low for the year, and that a substantial increase could come on any positive news, but don't know when that will occur. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next